Quantum Private Wealth LLC Sells 16,499 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Quantum Private Wealth LLC reduced its position in Exact Sciences Co. (NASDAQ:EXAS) by 26.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,775 shares of the medical research company’s stock after selling 16,499 shares during the quarter. Exact Sciences makes up about 0.8% of Quantum Private Wealth LLC’s holdings, making the stock its 21st largest position. Quantum Private Wealth LLC’s holdings in Exact Sciences were worth $2,572,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. AMF Tjanstepension AB bought a new stake in shares of Exact Sciences in the third quarter valued at approximately $724,000. CWM LLC increased its position in shares of Exact Sciences by 68.4% during the third quarter. CWM LLC now owns 10,454 shares of the medical research company’s stock valued at $712,000 after buying an additional 4,248 shares during the period. Creative Planning boosted its position in shares of Exact Sciences by 14.8% in the third quarter. Creative Planning now owns 38,060 shares of the medical research company’s stock valued at $2,593,000 after acquiring an additional 4,906 shares during the period. V Square Quantitative Management LLC bought a new stake in Exact Sciences during the 3rd quarter worth approximately $47,000. Finally, Blue Trust Inc. boosted its holdings in Exact Sciences by 61.0% in the 3rd quarter. Blue Trust Inc. now owns 5,220 shares of the medical research company’s stock valued at $356,000 after purchasing an additional 1,978 shares during the period. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Price Performance

Shares of EXAS stock opened at $49.31 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. The firm has a market cap of $9.13 billion, a P/E ratio of -42.14 and a beta of 1.24. The business’s 50 day moving average price is $56.15 and its 200-day moving average price is $60.18. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Analysts Set New Price Targets

A number of equities analysts have weighed in on EXAS shares. Benchmark restated a “buy” rating and issued a $65.00 target price on shares of Exact Sciences in a research note on Monday, January 13th. Bank of America reduced their target price on Exact Sciences from $75.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Craig Hallum dropped their price target on Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Evercore ISI decreased their price objective on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein boosted their target price on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.